Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old.
Roland Bruno WalterVictoria PotterCharles F CraddockPublished in: Blood (2024)
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults age ≥70 with AML. However, while potentially curative, non-relapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving non-transplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.
Keyphrases
- acute myeloid leukemia
- stem cell transplantation
- bone marrow
- healthcare
- hematopoietic stem cell
- allogeneic hematopoietic stem cell transplantation
- free survival
- palliative care
- case report
- cardiovascular events
- high dose
- cardiovascular disease
- type diabetes
- rectal cancer
- cell proliferation
- affordable care act
- prognostic factors
- smoking cessation